The TAXUS Libert e Post-Approval Study (TL-PAS) is a prospective, multicenter US registry which enrolled 4199 patients, of which 1592 were defined as "on-label", i.e. treated as per the FDA-approved labeling for TL. Unique features of this registry include the TL stent and exclusive use of at least 12 months of prasugrel as part of a dual antiplatelet therapy (DAPT) strategy after stenting. Previous work demonstrated that in-hospital major adverse cardiac events (MACE) were favorable when compared to the TAXUS Express ARRIVE registries, which utilized the TAXUS Express (TE) stent and clopidogrel. Methods: Patients were enrolled at 82 sites between December 2009 -January 2012. After stenting, patients were prescribed aspirin and prasugrel (5 mg or 10 mg doses, as appropriate) for 12 months. Statistical testing was performed to determine if the primary endpoint of 12-month cardiac death or MI for the TL stent was non-inferior to the TE stent. A total of 2463 "on-label" patients receiving the TL stent from the TL-PAS (n¼1592) and TAXUS ATLAS Workhorse studies (WH; n¼871) were compared to the 3676 "on-label" TE-treated patients in the control arm of TAXUS ATLAS WH (n¼978) and ARRIVE 1/2 registries (n¼2698). Secondary outcomes including MACE (death, MI or target vessel failure), stent thrombosis and GUSTO moderate/severe bleeding are reported in the overall and "on-label" populations of TL-PAS. Results: Rates of the primary endpoint of cardiac death and MI were 3.0% (108/3554) with TE and 2.2% (52/2384) with TL; thus the criteria for non-inferiority were met (p<0.0001). Low rates of other adverse cardiac outcomes and bleeding were observed (Table) and were lower in the on-label group.
Background:
The TAXUS Libert e Post-Approval Study (TL-PAS) is a prospective, multicenter US registry which enrolled 4199 patients, of which 1592 were defined as "on-label", i.e. treated as per the FDA-approved labeling for TL. Unique features of this registry include the TL stent and exclusive use of at least 12 months of prasugrel as part of a dual antiplatelet therapy (DAPT) strategy after stenting. Previous work demonstrated that in-hospital major adverse cardiac events (MACE) were favorable when compared to the TAXUS Express ARRIVE registries, which utilized the TAXUS Express (TE) stent and clopidogrel. Methods: Patients were enrolled at 82 sites between December 2009 -January 2012. After stenting, patients were prescribed aspirin and prasugrel (5 mg or 10 mg doses, as appropriate) for 12 months. Statistical testing was performed to determine if the primary endpoint of 12-month cardiac death or MI for the TL stent was non-inferior to the TE stent. A total of 2463 "on-label" patients receiving the TL stent from the TL-PAS (n¼1592) and TAXUS ATLAS Workhorse studies (WH; n¼871) were compared to the 3676 "on-label" TE-treated patients in the control arm of TAXUS ATLAS WH (n¼978) and ARRIVE 1/2 registries (n¼2698). Secondary outcomes including MACE (death, MI or target vessel failure), stent thrombosis and GUSTO moderate/severe bleeding are reported in the overall and "on-label" populations of TL-PAS. Results: Rates of the primary endpoint of cardiac death and MI were 3.0% (108/3554) with TE and 2.2% (52/2384) with TL; thus the criteria for non-inferiority were met (p<0.0001). Low rates of other adverse cardiac outcomes and bleeding were observed (Table) and were lower in the on-label group.
Conclusions: The 1 year TL-PAS primary endpoint results show low rates of cardiac death/ MI (as well as overall MACE, stent thrombosis, and bleeding) utilizing a strategy of TAXUS Liberté stent and DAPT including prasugrel.
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Benefit Background: Drug eluting stent (DES) has been vastly used for percutaneous coronary intervention (PCI), but its late restenosis has been reported and long term benefit has been questionable especially in large size stent. Methods: Consecutive 12276 patients who received PCI between 2004 and 2011 were included in the study. Patients were divided into 4 groups: small bare metal stent (BMS), large BMS, small DES and large DES group depending on kind and size of implanted stents. Small stent was defined as its size was 3.25mm or smaller. Large stent was defined as the others. Selection of each stent was decided by operators. Average observation period was 1488 days. Shortest and longest observation periods were 1 and 2647 days. All-cause mortality and target lesion revascularization (TLR) rate was compared. Hazard ratio (HR) of morality and TLR in small DES and large BMS compared to small BMS, and in large DES compared to large BMS and its 95% confidence intervals (CIs) were calculated with multivariate Cox regression analysis adjusted for patient background. Background: The aim of this registry is to evaluate the clinical performance of a new generation Sirolimus eluting stent system (Osiro) in a large patient population in standard clinical care. The Osiro is a unique hybrid solution that combines passive and active components. PROBIO passive coating encapsulates the stent and minimizes interaction between the metal stent and surrounding tissue. BIOlute active coating contains a highly biocompatible and biodegradable polymer. Methods: Between August 2011 and March 2012, 1,356 subjects were enrolled consecutively in this international, multicentric BIOFLOW-III all-comers registry using the Osiro Sirolimus eluting stent. Primary endpoint is Target Lesion Failure (TLF) at twelve months follow-up. Pre-specified subgroups were diabetes, small vessels, chronic total occlusion and acute myocardial infarction. Results: Nine hundred seventy one men (72%) and three hundred eighty five women were enrolled at 43 sites in 14 countries. The mean age was 66.1 AE 10.7, ranging from 29-91 years. Based on our preliminary data, the majority of subjects presented with hypertension 76%, hypercholesteremia 60%, smoker 55%, and diabetes 30% 48% of all stented vessels had a diameter 2.75mm, 4% presented with chronic total occlusion. Eleven percent of the subjects experienced unstable angina, 47% stable angina. Acute MI was seen in 33% of the subjects (NSTEMI 22%, STEMI 11%). The portion of elderly subjects (! 75 years) is represented by 25%. Ninety seven percent (1,321) follow up compliance at six months and ninety five percent (1,289) at twelve months were achieved. An unbiased patient population was seen in the registry with more than 52% type B2/C lesions. Moderate and severe calcification was observed in 31%. The Osiro hybrid stent system demonstrated excellent device (98.7%) and procedure success (98.2%). In this 
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